你好!欢迎访问 登录|立即注册

0576-88813233

|
当前位置:科瑞产品

雷帕霉素Rapamycin (Sirolimus)

雷帕霉素Rapamycin (Sirolimus) 53123-88-9
规格 价格 库存 数量
在线咨询 大包装询价 加入购物车
如您需要更多数量的报价,请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您,谢谢!
产品信息
产品名称:雷帕霉素Rapamycin (Sirolimus) 纯度:98%min
CAS NO:53123-88-9 溶解度:Soluble in DMSO
分子式:C51H79NO13 包装:可按客户要求包装。
分子量:914.18 贮存:Store at -20℃
质量控制
COA
备注说明

雷帕霉素Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of 0.1 nM, more potently than iRap and AP21967 with IC50 of 5 nM and 10 nM, respectively[1]. Rapamycin exerts its antitumor effect on malignant glioma cells by inducing autophagy and suggest that in malignant glioma cells a disruption of the PI3K/Akt signaling pathway could greatly enhance the effectiveness of mTOR inhibitors. Rapamycin inhibits cell viability in all three cell lines in a dose-dependent manner, but their sensitivities varied. The IC50 levels of T98G, U87-MG, and U373-MG cells are 2 nM, 1 μM, and >25 μM, respectively[3].Treatment with Rapamycin (i.p, 1.5 mg/kg) almost completely prevents the hypertrophic increases in plantaris muscle weight and fibre size at 7 and 14 days[4]. WT or LS/+ mice are treated daily Rapamycin (2 mg/kg body weight i.p.) for 4 weeks, follows by an additional 4 weeks of weekly injections of the same dose. There is significant reversal of the abnormal fetal gene expression profile of hearts from Rapamycin-treated LS/+ mice[5].

版权所有 Copyright(C) 2018-2021 台州市科瑞生物技术有限公司

技术支持:kerui  浙ICP备09021343号
公司所列产品中涉及到专利,只供研发使用,不做销售;管制产品将严格遵守中国法律和购买客户国法律的规定销售,所有产品都不适用于人用 如被销售到构成专利侵权的国家,则相应的一切风险将由买方承担。